Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Breast 1

Conditions

Thrombocytopenia 1Purpura, Thrombocytopenic, Idiopathic 1Purpura, Thrombocytopenic 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Gastrointestinal Neoplasms 1Colorectal Neoplasms 1Chemotherapy-induced Thrombocytopenia 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Paclitaxel 79Carboplatin 64Bevacizumab 33liposomal doxorubicin 29Topotecan 28Gemcitabine 25Cisplatin 19olaparib 18Drug Therapy 12Doxorubicin 12Taxes 11niraparib 9Docetaxel 6CP protocol 6Trabectedin 5Hyperthermic Intraperitoneal Chemotherapy 5Etoposide 5Cyclophosphamide 51-dodecylpyridoxal 5rucaparib 4pembrolizumab 4avelumab 4atezolizumab 4Immunoglobulin G 4Ifosfamide 4Disulfides 4Dexamethasone 4Chemotherapy, Adjuvant 4trebananib 3fluzoparib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Ovarian Neoplasms × romiplostim × Clear all
NCT03937154 2026-04-07

Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer

Amgen

Phase 3 Active not recruiting
145 enrolled
BreastGynecologicThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡